Media coverage about NuVasive (NASDAQ:NUVA) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NuVasive earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news stories about the medical device company an impact score of 45.4927292801213 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s analysis:
- Intraoperative Neuromonitoring Market – Global Opportunity Analysis and Industry Forecast, 2014-2022 (prnewswire.com)
- Global Spine Market 2017-2021 with Focus on Spinal Fusion: Industry Analysis & Outlook – Rising Cases of Spinal Cord Injury Driving the Market – Research and Markets (businesswire.com)
- NuVasive Q4 Preliminary Results Fail to Cheer Investors (finance.yahoo.com)
- NuVasive (NUVA) Rating Reiterated by Piper Jaffray Companies (americanbankingnews.com)
- Celgene, Dave& Buster’s slide while Kohl’s and Crocs rise (latimes.com)
Shares of NuVasive (NASDAQ:NUVA) opened at $52.61 on Thursday. The stock has a market capitalization of $2,710.00, a PE ratio of 44.21, a price-to-earnings-growth ratio of 1.63 and a beta of 0.77. The company has a current ratio of 2.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.76. NuVasive has a fifty-two week low of $49.25 and a fifty-two week high of $81.68.
NuVasive announced that its Board of Directors has initiated a share buyback program on Tuesday, October 24th that allows the company to buyback $100.00 million in shares. This buyback authorization allows the medical device company to purchase shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.
A number of research analysts recently issued reports on NUVA shares. Piper Jaffray Companies reiterated a “buy” rating and issued a $90.00 target price on shares of NuVasive in a report on Tuesday. Needham & Company LLC reiterated a “sell” rating on shares of NuVasive in a report on Wednesday, October 25th. Robert W. Baird set a $60.00 target price on NuVasive and gave the company a “hold” rating in a report on Thursday, October 12th. BMO Capital Markets decreased their target price on NuVasive from $85.00 to $69.00 and set an “outperform” rating for the company in a report on Wednesday, October 25th. Finally, Royal Bank of Canada decreased their target price on NuVasive from $75.00 to $70.00 and set an “outperform” rating for the company in a report on Friday, November 10th. One analyst has rated the stock with a sell rating, three have issued a hold rating and fourteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $72.33.
ILLEGAL ACTIVITY WARNING: This news story was reported by BBNS and is the sole property of of BBNS. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/nuvasive-nuva-receiving-somewhat-favorable-news-coverage-analysis-shows/1824365.html.
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with our FREE daily email newsletter.